Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen

March 17, 2017 11:23 AM EDT

Cowen analyst Eric Schmidt weighed in on Amgen (NASDAQ: AMGN) after the highly anticipated FOURIER CV outcomes data details were presented at ACC. The firm maintained an Outperform rating and price target of $209 on AMGN. He said the results were "good enough" to gradually transform... More

While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs

March 17, 2017 11:05 AM EDT

Goldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes trial, FOURIER, was presented.

Flynn commented, "In our view the primary endpoint effect is likely below investor expectations (hence why AMGN... More